Year: 2023

GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 7 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About AltimmuneAltimmune is a clinical-stage biopharmaceutical company...

BOCA RATON, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the third quarter ended September 30, 2023, after the market closes on Tuesday, November 14, 2023. Management will host a conference call and audio webcast on Tuesday, November 14, 2023, at 5:00 p.m. ET to discuss the Company’s financial results.Event: Third Quarter 2023 Financial Results Conference CallDate: Tuesday, November 14, 2023Time: 5:00 p.m. Eastern TimeLive Call: 1-844-826-3035 (U.S. & Canada Toll-Free)Conference ID 10183775Webcast: RegisterFor interested individuals unable to join the conference call, a webcast of the call will be available until December...

Following the reverse share split, the Company will have approximately 1,188,805 Ordinary Shares issued and outstanding. TEL AVIV, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) — Jeffs’ Brands Lt. (Nasdaq: JFBR) (“Company” or “Jeffs’ Brands”) a data-driven e-commerce company operating on the Amazon Marketplace, announced today that it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-7. The Company’s Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on November 3, 2023, under the Company’s existing trading symbol “JFBR”. The trading symbol “JFBRW” and CUSIP number for the Company’s public warrants will remain unchanged following the reverse share split. The reverse share split was approved by the Company’s shareholders...

ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee is meeting today to review the Biologics License Application (BLA) for exagamglogene autotemcel (exa-cel) for the treatment of sickle cell disease (SCD) in people ages 12 and older with recurrent vaso-occlusive crises. The Advisory Committee meeting is scheduled for 9:00 AM ET. The briefing materials can be found on the FDA website HERE. The Prescription Drug User Fee Act date for completion of the review of the BLA for exa-cel for SCD is December 8,...

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scientific Officer; and Vignesh Rajah, Chief Medical Officer. Conference call and webcast details:Investors (domestic): 877-407-0792Investors...

ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (U.S.) or 973-528-0011 (international) and entering conference code: 971200. The Company suggests participants join 15 minutes in advance of the event. About...

SANTA MONICA, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) has released its Third Quarter 2023 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at www.macerich.com. As previously announced, management will hold a conference call at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) today, Tuesday, October 31, 2023, to discuss quarterly results. Participants who wish to join the conference by telephone must register at the dial-in registration link below to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the webcast registration link below or in the Investors Section of the company’s website at https://investing.macerich.com/. Dial-In Registration:...

Press Release Nokia Technology Strategy 2030: emerging technology trends and their impact on networksNokia’s Technology Strategy 2030 is fundamental to realizing the full potential of AI, cloud and other emerging trends with connectivity at the center enabling the adoption of these technologies Demand on global telecom networks from 2022 to 2030 will grow at a CAGR of 22% – 25% according to Nokia Global Network Traffic 2030 report Nokia’s future network architecture as proposed in the Technology Strategy 2030 is vital for the next phase of digital transformation for Nokia and its customers31 October 2023Espoo, Finland – Nokia today presents its Technology Strategy 2030 that identifies trends and emerging technologies that will shape technology, networks and the world for the next seven years. According to its new Global Network...